Clinical Trial Update: Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of ACZ885 (canakinumab) in patients with NLRP3 mutations presenting CAPS…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndrome
• Familial Cold Autoinflammatory Syndrome
• Muckle-wells Syndrome

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: NALP3 Mutation | Phase 2 | Status: COMPLETED